Top Gainers Technical Data -- Research on Zix, Textura, Recon Technology, and Anthera Pharma - WTRF 7 News Sports Weather - Wheeling Steubenville

Top Gainers Technical Data -- Research on Zix, Textura, Recon Technology, and Anthera Pharma

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Investor-Edge

Editor Note: For more information about this release, please scroll to bottom

LONDON, May 16, 2014 /PRNewswire/ --


The US markets saw a negative sentiment on Thursday, May 15, 2014, with the NASDAQ Composite closing at 4,069.29, down 0.76%, the Dow Jones Industrial Average ending the session 1.01% lower at 16,446.81, and the S&P 500 edging 0.94% lower to finish the trading session at 1,870.85. During the session, Materials, Energy and Financials sectors ended in negative, while some positive momentum was observed in the Telecommunication Services sector. A number of stocks saw large movements, including Zix Corporation (NASDAQ: ZIXI), Textura Corporation (NYSE: TXTR), Recon Technology Ltd (NASDAQ: RCON) and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Free technical research on ZIXI, TXTR, RCON and ANTH can be downloaded upon signing up at:

http://www.investor-edge.com/2637-register

On Thursday, shares in Zix Corp. fluctuated between $3.24 and $3.56 before ending the session 9.00% higher at $3.39. Zix Corp.'s stock reported a trading volume of 1.44 million shares, much above to its three months average volume of 0.43 million shares. Zix Corp.'s shares have declined 15.25% in the last one month and 25.66% since start of this year. However, the stock has surged 6.27% in the previous three trading sessions. The S&P 500 Information Technology Sector Index registered a loss of 0.79% during the trading session, while it has charted up 1.55% in the last one month. The stock is trading below its 50-day and 200-day moving averages of $3.89 and $4.38, respectively. Moreover, shares of the company traded at a PE ratio of 18.66 and have a Relative Strength Index (RSI) of 18.52. Sign up today to read free research on ZIXI at:

http://www.investor-edge.com/2637-ZIXI-16May2014.pdf

Shares in Textura Corp. recorded a trading volume of 1.06 million shares, higher than its three months average volume of 0.49 million shares, on Thursday. The stock ended the day at $18.94, which was 8.23% above its previous day's closing, and registered an intraday range of $17.89 and $19.52. Textura Corp.'s shares have declined 5.06% in the in the last one month and 36.74% since from the beginning of 2014. However, the stock has surged 15.84% previous three trading sessions. The stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $31.86 is above its 50-day moving average of $22.54. Furthermore, shares of the company have an RSI of 42.03. On May 15, 2014, Textura Corp. announced that Wespec Construction has used Textura CPM on over 500 projects since 2005, ranging in size from a few thousand dollars to over $40 million in value. Sign up today to read free research on TXTR at:

http://www.investor-edge.com/2637-TXTR-16May2014.pdf

Recon Technology Ltd's stock finished Thursday's session 16.44% higher at $4.25. A total of 0.91 million shares were traded, which was above its three months average volume of 0.18 million shares. The stock moved between $3.67 and $4.58 during the session. Shares of the company traded at a PE ratio of 13.55. Although, Recon Technology Ltd's shares have plummeted 12.91% in the last one month, it has advanced 13.03% in the previous three trading sessions and 37.97% on YTD basis. The stock is trading above 200-day moving average. The stock's 50-day moving average of $4.83 is above its 200-day moving average of $3.91. The stock has an RSI of 32.41. On the same day, Recon Technology Ltd announced its Q3 FY 2014 financial results (period ended March 31, 2014). For Q3 FY 2014, the company reported net loss attributable to Recon Technology of $0.31 million, or $0.07 per diluted share. Sign up today to read free research on RCON at:

http://www.investor-edge.com/2637-RCON-16May2014.pdf

Anthera Pharmaceuticals Inc.'s stock rallied 10.29%, closing the day at $3.00. The stock recorded a trading volume of 0.91 million shares, higher than its three months average volume of 0.11 million shares. The stock oscillated between $2.65 and $3.15 during the trading session. Anthera Pharmaceuticals Inc.'s stock has gained 9.89% in the previous three trading sessions and 6.76% in the last one month. However, the stock has lost 2.28% since start of this year. The S&P 500 Health Care Sector Index reported a loss of 1.03% during the trading session while the index has charted up 2.23% in the last one month. Additionally, Anthera Pharmaceuticals Inc.'s stock has an RSI of 38.76. Sign up today to read free research on ANTH at:

http://www.investor-edge.com/2637-ANTH-16May2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


©2012 PR Newswire. All Rights Reserved.